Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | NAPEPLD | Q6IQ20 | 9/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19119313 | 0.88 | ROCK2 (0.43) | ROCK2ROCK1PIK3CBSRCNAPEPLD | |
| SCHEMBL354322 | 0.86 | ROCK2 (0.45) | ROCK2ROCK1SRCSCDSCD5 | |
| SCHEMBL352905 | 0.83 | ROCK2 (0.47) | ROCK2ROCK1SRCATG4B | |
| SCHEMBL354374 | 0.79 | ROCK2 (0.44) | ROCK2ROCK1SRCATG4B | |
| SCHEMBL353559 | 0.79 | ROCK2 (0.52) | ROCK2ROCK1AKT1SCD5ATG4B | |
| SCHEMBL353551 | 0.79 | ROCK2 (0.44) | ROCK2ROCK1SRCATG4B | |
| SCHEMBL353119 | 0.79 | NAMPT (0.49) | ROCK2ROCK1SRCAKT1ATG4B | |
| SCHEMBL354366 | 0.79 | ROCK2 (0.51) | ROCK2ROCK1AKT1ATG4B | |
| SCHEMBL352897 | 0.79 | ROCK1 (0.51) | ROCK2ROCK1AKT1ATG4B | |
| SCHEMBL353812 | 0.79 | ROCK2 (0.51) | ROCK2ROCK1AKT1SCD5ATG4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | claimed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | claimed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | ROCK2 4626/4885ROCK1 4747/4885PIK3CB 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.